Related Experiment Video

Updated: Jul 25, 2025

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.6K

Role of Iron Therapy in Heart Failure: A Consensus Statement from India

H K Chopra1, G S Wander2, Tiny Nair3

  • 1Senior Consultant, Department of Cardiology, Medanta Moolchand Heart Institute, Delhi.

The Journal of the Association of Physicians of India
|June 24, 2023
PubMed

Insights

Iron deficiency (ID) is common in heart failure (HF) patients and linked to worse outcomes. Intravenous ferric carboxymaltose (FCM) is a new treatment option for ID in HF, improving patient health and quality of life.

Area of Science:

  • Cardiology
  • Hematology

Background:

  • Iron deficiency (ID) is prevalent in heart failure (HF) patients, impacting both acute HF (AHF) and chronic HF (CHF).
  • Uncorrected ID correlates with increased hospitalization rates and mortality in HF patients.
  • ID is emerging as a significant comorbidity and a therapeutic target in chronic heart failure (CHF).

Purpose of the Study:

  • To provide expert consensus on diagnosing ID in HF patients.
  • To outline patient profiles suitable for intravenous ferric carboxymaltose (FCM) therapy.
  • To guide the administration and monitoring of IV FCM in HF patients.

Main Methods:

  • Consensus-based recommendations.
  • Expert opinion synthesis.
  • Review of clinical evidence for IV FCM in HF.

Main Results:

  • Intravenous ferric carboxymaltose (FCM) effectively reduces hospitalization risk associated with HF exacerbations.
  • FCM treatment leads to improvements in functional capacity among HF patients.
  • Patient-reported quality of life (QOL) is enhanced with FCM therapy.

Conclusions:

  • ID is a critical, treatable comorbidity in HF.
  • IV FCM is a valuable therapeutic option for selected HF patients with ID.
  • Standardized diagnostic and treatment protocols for ID in HF are recommended.

More Related Videos

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism05:36

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

517
Gene Transfer for Ischemic Heart Failure in a Preclinical Model07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

12.9K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
15
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
467
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
111
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
640
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
371